Can a sleep pill boost success in opioid treatment?

NCT ID NCT05145764

First seen Aug 10, 2026 · Last updated Aug 11, 2026 · Updated 1 time

Summary

This study tests whether adding the sleep medication suvorexant to standard buprenorphine treatment can improve sleep and medication adherence in people with opioid use disorder who have recently used fentanyl. Participants first stay in a residential setting for five days to start buprenorphine, then continue treatment as outpatients for three weeks. The trial compares suvorexant against a placebo, measuring sleep quality and how consistently participants take their buprenorphine.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
suvorexant
What this could lead to
If it works, adding suvorexant to standard buprenorphine treatment could improve sleep and help people stick with their recovery medication, potentially reducing relapse.
What could go wrong
This is a small, early-stage trial, so results may not hold up in larger studies. Suvorexant can cause side effects like drowsiness or unusual sleep behaviors, and its benefit for opioid use disorder is unproven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OPIOID-USE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Johns Hopkins Bayview Medical Center

    Baltimore, Maryland, 21224, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.